AMP Capital Investors Ltd cut its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 77,407 shares of the company’s stock after selling 24,723 shares during the period. AMP Capital Investors Ltd owned 0.09% of IDEXX Laboratories worth $12,036,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in the company. WMS Partners LLC increased its stake in shares of IDEXX Laboratories by 0.3% during the 2nd quarter. WMS Partners LLC now owns 1,583 shares of the company’s stock worth $256,000 after purchasing an additional 4 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS boosted its holdings in shares of IDEXX Laboratories by 0.3% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 6,547 shares of the company’s stock worth $1,057,000 after buying an additional 19 shares during the period. Strs Ohio boosted its holdings in shares of IDEXX Laboratories by 0.7% during the 2nd quarter. Strs Ohio now owns 5,929 shares of the company’s stock worth $957,000 after buying an additional 41 shares during the period. National Asset Management Inc. boosted its holdings in shares of IDEXX Laboratories by 2.1% during the 2nd quarter. National Asset Management Inc. now owns 2,051 shares of the company’s stock worth $332,000 after buying an additional 42 shares during the period. Finally, Advisor Group Inc. boosted its holdings in shares of IDEXX Laboratories by 1.1% during the 2nd quarter. Advisor Group Inc. now owns 4,998 shares of the company’s stock worth $732,000 after buying an additional 52 shares during the period. Institutional investors own 86.80% of the company’s stock.
Several brokerages recently commented on IDXX. Stifel Nicolaus reaffirmed a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a report on Tuesday, October 24th. Bank of America raised shares of IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $175.00 target price for the company in a report on Wednesday, August 23rd. Canaccord Genuity reaffirmed a “buy” rating and set a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, August 22nd. Finally, Zacks Investment Research downgraded shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Wednesday, October 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. IDEXX Laboratories currently has a consensus rating of “Hold” and a consensus target price of $173.67.
Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) opened at $160.57 on Monday. The company has a quick ratio of 0.77, a current ratio of 0.95 and a debt-to-equity ratio of -12.48. The stock has a market cap of $14,000.00, a PE ratio of 54.06, a price-to-earnings-growth ratio of 2.43 and a beta of 0.42. IDEXX Laboratories, Inc. has a twelve month low of $113.92 and a twelve month high of $173.01.
IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, October 31st. The company reported $0.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.05. The firm had revenue of $492.00 million during the quarter, compared to the consensus estimate of $492.94 million. IDEXX Laboratories had a net margin of 14.55% and a negative return on equity of 336.64%. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.62 EPS. equities research analysts expect that IDEXX Laboratories, Inc. will post 3.24 earnings per share for the current fiscal year.
In other news, insider Giovani Twigge sold 2,000 shares of the business’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $156.07, for a total value of $312,140.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Jonathan W. Ayers sold 54,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 7th. The shares were sold at an average price of $151.32, for a total transaction of $8,171,280.00. Following the completion of the transaction, the chairman now owns 1,064,573 shares of the company’s stock, valued at $161,091,186.36. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock valued at $16,686,200 in the last three months. Insiders own 2.77% of the company’s stock.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).
Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.